The Urologic Oncology Branch conducts clinical and basic research designed to develop better methods for detecting, preventing, and treating patients with kidney cancer, prostate cancer and bladder cancer. We evaluate and manage patients with non-inherited as well as inherited forms of kidney cancer. The Branch also has an expanding prostate cancer program. Patients with known or suspected localized and locally advanced prostate cancer undergo advanced MRI imaging followed by fusion image-guided biopsy to diagnose and characterize the cancer. They may then be managed with robotic surgery or be followed with active surveillance and intermittent imaging. In addition, we have a growing program in genomics and targeted therapy for bladder cancer patients, including therapy that targets EGFR, FGFR3 and other mutated bladder cancer genes.

Our highly trained physicians develop and conduct a wide range of clinical trials in a quest to develop the medicines of tomorrow for patients with cancer, HIV or immunodeficiency disorders.  All of our trials take place at the NIH Clinical Center in Bethesda, MD, the world's largest research hospital, and through telehealth.  Once you are enrolled in a clinical trial at the Clinical Center, medical care is free.